UTHR vs XERS

United Therapeutics Corporation vs Xeris Biopharma Holdings, Inc. — Valuation Comparison 2026

UTHR

Drug Manufacturers - Specialty & Generic
United Therapeutics Corporation
Quality
10.0
out of 10
Value Trap
Price
$562.09
Last close
Models
13/13
Active
VS

XERS

Drug Manufacturers - Specialty & Generic
Xeris Biopharma Holdings, Inc.
Quality
8.6
out of 10
Value Trap
35
LOW
Price
$6.32
Last close
Models
11/13
Active

Model-by-Model Comparison

ModelType UTHR Fair ValueUTHR Upside XERS Fair ValueXERS Upside
Bayesian DCF Intrinsic $429.25 -23.6% $1.44 -77.1%
Earnings Power Value Intrinsic $248.41 -55.8% $0.13 -97.9%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for UTHR vs XERS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

UTHR vs XERS — Which Stock Is More Undervalued?

UTHR scores higher with a 10.0/10 quality rating vs XERS's 8.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing United Therapeutics Corporation (UTHR) and Xeris Biopharma Holdings, Inc. (XERS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

UTHR currently trades at $562.09 with a QOC of 10.0/10, while XERS trades at $6.32 with a QOC of 8.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).